Sirona Biochem boasts of TFC-1326 trial results 2023-04-26 09:47 ET - News Release
Dr. Geraldine Deliencourt-Godefroy reports
SIRONA BIOCHEM ANNOUNCES EXCEPTIONAL CLINICAL TRIAL RESULTS FOR ANTI-AGING COMPOUND TFC-1326
Sirona Biochem Corp.'s clinical trial results for novel anti-aging compound TFC-1326 have exceeded even high expectations on key criteria.
The trial, which was completed by a leading contract research organization in Paris, France, was independently financed by Sirona to ensure that results can be shared with interested partners, without restrictions. Full results will be published in a scientific journal.
The clinical trial was designed to assess the compound's efficacy to reverse aging facial skin, including restoring lost volume and reducing fine wrinkles. The formulation is a cream base with TFC-1326 at a concentration of 1 per cent and no other active ingredient.
The following key scientific results were shown during the trial:
- 37-per-cent increase in skin density;
- 54-per-cent decrease in H202 (exceptional anti-oxidant). Oxidation is a major cause of skin aging;
- 54-per-cent decrease in IL-8 (exceptional anti-inflammatory). Inflammation is also a major cause of skin aging;
- 25-per-cent increase in skin radiance;
- 14-per-cent improvement in facial skin laxity, which is a remodelling effect on the oval of the face.
The following results were collected from participants:
- 80 per cent of participants felt their skin was firmer;
- 90 per cent of participants felt an improvement in the quality of the skin;
- 100 per cent of participants reported the product was well tolerated, even on sensitive skin;
- 95 per cent of participants reported being happy with the product;
- 75 per cent of participants reported a visible reduction in wrinkles;
- 90 per cent reported improved skin hydration.
Both measured and subjective parameters showed continued improvement through the 12-week study, indicating further improvement likely with longer use.
The results support the strong preclinical data, including clinical safety data. A basic formulation was utilized in the clinical trial to confirm all benefits were specifically attributable to TFC-1326 and not other active ingredients.
"We have achieved results that exceed those seen from currently marketed anti-aging therapies. Our photographic results show a remodelling effect of the jowl and cheek area which is truly unprecedented in topical application. In the world of aesthetics positive visual results delivered safely, without adversity, is an ultimate gaol and has been achieved during this trial. We believe even more outstanding results are possible through planned modifications in our formulation and knowledge we have gained from this study," reports Dr. Geraldine Deliencourt-Godefroy, chief scientific officer.
Sirona is currently engaging industry experts to determine the best path forward to commercialize TFC-1326. Further updates will be provided once the strategy is finalized.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and continuing royalty payments. Sirona's laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants.